SCHEMBL3574049

SCHEMBL3574049

CCOC(=O)c1cnc2oc(-c3ccc(OCCN(C)C)cc3)c(-c3ccccc3)c2c1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 7/20 0.52
LCK P06239 3/20 0.49
CCNB2 O95067 1/20 0.49
CDK1 P06493 1/20 0.49
CCNB1 P14635 1/20 0.49
CCNA2 P20248 1/20 0.49
CCNE1 P24864 1/20 0.49
CDK2 P24941 1/20 0.49
CCNB3 Q8WWL7 1/20 0.49
AURKA O14965 1/20 0.43
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP1A2 P05177 2/20 0.41
POLB P06746 2/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
RAD52 P43351 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3568276 0.82 TNK2 (0.57) TNK2LCKKMT2AMEN1ALDH1A1
SCHEMBL13462163 0.77 TNK2 (0.60) TNK2LCKKMT2AMEN1ALDH1A1
SCHEMBL3566031 0.75 TNK2 (0.55) TNK2LCKKMT2AMEN1ALDH1A1
SCHEMBL2973750 0.73 TNK2 (0.65) TNK2LCKKMT2AMEN1ALDH1A1
SCHEMBL5254922 0.73 TNK2 (0.52) TNK2LCKKMT2AMEN1ALDH1A1
SCHEMBL5255902 0.72 TNK2 (0.52) TNK2LCKKMT2AMEN1ALDH1A1
SCHEMBL13436263 0.71 TNK2 (0.51) TNK2LCKKMT2AMEN1ALDH1A1
SCHEMBL2970697 0.70 TNK2 (0.73) TNK2LCKAURKAKMT2AMEN1
SCHEMBL5253617 0.69 TNK2 (0.57) TNK2LCKKMT2AMEN1ALDH1A1
SCHEMBL13462162 0.69 TNK2 (0.57) TNK2LCKKMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US claimed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 US claimed
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US disclosed
EP-1791845-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2007-06-06 EP disclosed
WO-2006130160-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2006-12-07 WO disclosed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046977-A1 Furanopyridine derivatives and methods of use LCK, NFATC1, MINK1 TNK2 22/4885LCK 1/4885CCNB2 3050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.